ClinicalTrials.gg
TerminatedNCT06784973Updated Jun 8, 2026Results posted

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

A Phase 2 interventional study of Obeldesivir and Obeldesivir Placebo in RSV Infection, sponsored by Gilead Sciences. Terminated at 56 sites in 2 countries. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated by Sponsor; the decision was not due to any safety findings.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
Up to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.

Enrollment
118th of 122
4 · median 88
Started
2025
with 7 others
Phase 2
28 of 145
2 open now
Registered
136th of 145
by date
Lead sponsor
6 of 145
Gilead Sciences

Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 118th largest by enrollment of the 122 interventional ones that give a count, is one of 8 that started in 2025, is one of 28 in phase 2, and was the 136th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: Up to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Respiratory Syncytial Virus Infections with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection. It will also look at how well ODV helps reduce the time it takes for children to feel better and for their RSV symptoms to improve.

The primary objectives of this study are: a) to evaluate the safety and tolerability of ODV in pediatric participants with RSV infection; b) To evaluate the efficacy of ODV on time to alleviation of targeted RSV symptoms in pediatric participants with RSV infection.

Read the detailed description

Pediatric participants will be enrolled as follows:

  • Cohort 1: Infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to \< 40 kg
  • Cohort 2: Neonates, either born at term or preterm, weighing ≥ 1.5 kg to \< 6 kg
03

Conditions studied

  • RSV Infection
04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants assigned male or female at birth, from birth to \< 5 years of age who meet one of the following criteria, where permitted according to local law and approved nationally and by relevant institutional review board or independent ethics committee:

    • Cohort 1: Infants and children from 4 weeks postnatal age, weighing ≥ 3 kg to \< 40 kg (Part A) and ≥ 1.5 kg to \< 3 kg (Part B)
    • Cohort 2: Neonates, either born at term or preterm, weighing ≥ 1.5 kg to \< 6 kg
  • RSV infection diagnosis ≤ 3 days prior to randomization.
  • Negative test for influenza A/B, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection) ≤ 7 days prior to randomization.
  • Onset of RSV signs or symptoms ≤ 3 days prior to randomization.
  • Presence of at least 1 sign or symptom of RSV infection at screening and at randomization.

Key Exclusion Criteria:

  • Currently requiring or expected to require hospitalization for RSV infection within 48 hours after randomization.
  • Not expected to survive the current RSV-related illness.
  • Documented previous infection and/or hospitalization for RSV during the current respiratory virus season.
  • Diagnosed with acute concurrent active systemic infections requiring treatment with systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy, or with any documented respiratory viral infection (other than RSV), ≤ 7 days prior to randomization.
  • History of asthma or recurrent wheezing.
  • Neuromuscular disease that affects swallowing.
  • Cystic fibrosis.
  • Participants who are .
  • ≥ 5 × (ULN).
  • Abnormal renal function.
  • Concurrent or previous treatment with other agents with actual or possible direct antiviral activity against RSV, received within 28 days or within 5 half-lives, whichever is longer, prior to randomization.
  • Received palivizumab within 100 days, or nirsevimab within 1 year, or other RSV specific monoclonal antibody within 5 half-lives of the antibody, prior to randomization.
  • Participant whose mother received RSV vaccination during pregnancy and who is \< 1 year old prior to randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Cohort 1: Part A (Group 2) - Obeldesivir (ODV)

    Participants weighing ≥ 12 kg to \< 20 kg, will receive ODV 175 mg, orally, twice on Day 1, followed by ODV 116.6 mg, orally, twice daily on Days 2 to 5.

    Drug: Obeldesivir

  • Experimental
    Cohort 1: Part A (Group 3) - ODV

    Participants weighing ≥ 6 kg to \< 12 kg, will receive ODV 116.6 mg, orally, twice on Day 1, followed by ODV 58.3 mg, orally, twice daily on Days 2 to 5.

    Drug: Obeldesivir

  • Placebo comparator
    Cohort 1: Part A (Group 3) - Placebo

    Participants weighing ≥ 6 kg to \< 12 kg, will receive placebo-to-match ODV, orally, twice daily on Days 1 to 5.

    Drug: Obeldesivir Placebo

Interventions

  • Administered orally

    Also known as: ODV, GS-5245

  • DrugObeldesivir Placebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28

    TEAEs were defined as any adverse events that began on or after the date of first dose of study drug up to the date of last dose of study drug up to Day 28. The percentage of participants who experienced at least one TEAE was assessed from Day 1 through Day 28.

    Time frame: Up to Day 28

  2. Percentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 28

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose up to Day 28. A treatment-emergent laboratory abnormality severity was graded according to the Division of AIDS (DAIDS) Version 2.1. Grade 0: Values that do not meet the criteria for an abnormality of at least Grade 1;Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Potentially life-threatening. The percentage of participants who experienced Grade 3 or 4 laboratory abnormalities was assessed from Day 1 through Day 28.

    Time frame: Up to Day 28

  3. Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 28

    Alleviation of targeted RSV symptoms was defined as achievement of 2 consecutive daily assessments with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1, or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

    Time frame: Up to Day 28

Secondary outcomes

  1. PK Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir

    AUCtau is defined as area under the plasma concentration-time curve during a dosing interval (AUCtau) of GS-441524, the active metabolite of obeldesivir.

    Time frame: Day 5 (predose, 2.5, and 3.5 hours post-dose)

  2. PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir

    Cmax is defined as maximum plasma concentration of GS-441524, the active metabolite of obeldesivir.

    Time frame: Day 1 (0.25, 0.75, and 2 hours post-dose); Day 5 (predose, 2.5, and 3.5 hours post-dose)

  3. PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir

    Ctrough is defined as the trough observed drug concentration \[measured concentration at predose of Day 5 (taken directly before next administration)\].

    Time frame: Day 5: Predose

  4. Change From Baseline in RSV Nasal Swab Viral Load at Day 5

    Nasal swab samples was used to assess RSV viral load by reversetranscriptase-quantitative polymerase chain reaction (RT-qPCR), respiratory coinfection by multiplex respiratory pathogen PCR, potential infectious viral titer assessment, and potential resistance testing (by sequencing and/or phenotyping). Baseline was defined as the last available value collected on or prior to first dose of study drug.

    Time frame: Baseline, Day 5

  5. Time to Sustained Alleviation of Targeted RSV Symptoms by Day 28

    Sustained alleviation of targeted RSV symptoms was defined as 3 daily consecutive assessments (48-hour period) with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1; or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to sustained alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

    Time frame: Up to Day 28

  6. Time to Resolution of Targeted RSV Symptoms by Day 28

    Resolution of targeted RSV symptoms was defined as: for 2 daily consecutive assessments, improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score \>2; no increase or an improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score of 2; no increase in score for any targeted RSV symptom with baseline score of 1. The time to resolution of targeted RSV symptoms by Day 28 was calculated as the resolution date/time minus the first dose date/time. Targeted RSV symptoms referred to RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

    Time frame: Up to Day 28

  7. Number of Participants With Palatability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5

    Caregivers were asked to rate how the study drug tasted to their child. A questionnaire was administered to caregivers to assess palatability. Palatability was assessed by caregivers using a questionnaire on Day 1 and Day 5 with response options: Super Good, Good, Maybe Good or Maybe Bad, Bad, or Super Bad.

    Time frame: Days 1 and 5

  8. Number of Participants With Acceptability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5

    Caregivers were asked to evaluate how easy it was for children to take the study drug. A questionnaire was administered to caregivers to assess acceptability. Acceptability was assessed by caregivers using a questionnaire with response options: Super Easy, Easy, Maybe Easy or Maybe Hard, Hard, or Super Hard. The questionnaire evaluated how easy it was for children to take the study drug.

    Time frame: Days 1 and 5

07

Results

Posted Jun 8, 2026

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Started121
Completed111
Not completed010
Withdrew: Withdrew consent010

Outcome measures

PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28

TEAEs were defined as any adverse events that began on or after the date of first dose of study drug up to the date of last dose of study drug up to Day 28. The percentage of participants who experienced at least one TEAE was assessed from Day 1 through Day 28.

Time frame:
Up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28
percentage of participantsCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 280100.0100.0
PrimaryPercentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 28

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose up to Day 28. A treatment-emergent laboratory abnormality severity was graded according to the Division of AIDS (DAIDS) Version 2.1. Grade 0: Values that do not meet the criteria for an abnormality of at least Grade 1;Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Potentially life-threatening. The percentage of participants who experienced Grade 3 or 4 laboratory abnormalities was assessed from Day 1 through Day 28.

Time frame:
Up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 28
percentage of participantsCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Percentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 2800100.0
PrimaryTime to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 28

Alleviation of targeted RSV symptoms was defined as achievement of 2 consecutive daily assessments with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1, or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

Time frame:
Up to Day 28
Reported as:
Median · days
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 28
daysCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 285.4 (5.4 to 5.4)NA (NA to NA)—
SecondaryPK Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir

AUCtau is defined as area under the plasma concentration-time curve during a dosing interval (AUCtau) of GS-441524, the active metabolite of obeldesivir.

Time frame:
Day 5 (predose, 2.5, and 3.5 hours post-dose)
Reported as:
Mean · nanograms times hours per mL(ng*h/mL)
PK Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir
nanograms times hours per mL(ng*h/mL)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODV
PK Parameter: AUCtau of GS-441524, Metabolite of ObeldesivirNA ± NANA ± NA
SecondaryPK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir

Cmax is defined as maximum plasma concentration of GS-441524, the active metabolite of obeldesivir.

Time frame:
Day 1 (0.25, 0.75, and 2 hours post-dose); Day 5 (predose, 2.5, and 3.5 hours post-dose)
Reported as:
Mean · ng/mL
PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir
ng/mLCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODV
PK Parameter: Cmax of GS-441524, Metabolite of ObeldesivirNA ± NANA ± NA
SecondaryPK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir

Ctrough is defined as the trough observed drug concentration \[measured concentration at predose of Day 5 (taken directly before next administration)\].

Time frame:
Day 5: Predose
Reported as:
Mean · ng/mL
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir
ng/mLCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODV
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir960 ± NA159 ± NA
SecondaryChange From Baseline in RSV Nasal Swab Viral Load at Day 5

Nasal swab samples was used to assess RSV viral load by reversetranscriptase-quantitative polymerase chain reaction (RT-qPCR), respiratory coinfection by multiplex respiratory pathogen PCR, potential infectious viral titer assessment, and potential resistance testing (by sequencing and/or phenotyping). Baseline was defined as the last available value collected on or prior to first dose of study drug.

Time frame:
Baseline, Day 5
Reported as:
Number · log10 copies/mL
Change From Baseline in RSV Nasal Swab Viral Load at Day 5
log10 copies/mLCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Baseline4.898.45—
Change from Baseline at Day 5-2.79-2.12—
SecondaryTime to Sustained Alleviation of Targeted RSV Symptoms by Day 28

Sustained alleviation of targeted RSV symptoms was defined as 3 daily consecutive assessments (48-hour period) with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1; or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to sustained alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

Time frame:
Up to Day 28
Reported as:
Median · days
Time to Sustained Alleviation of Targeted RSV Symptoms by Day 28
daysCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Time to Sustained Alleviation of Targeted RSV Symptoms by Day 285.4 (5.4 to 5.4)NA (NA to NA)—
SecondaryTime to Resolution of Targeted RSV Symptoms by Day 28

Resolution of targeted RSV symptoms was defined as: for 2 daily consecutive assessments, improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score \>2; no increase or an improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score of 2; no increase in score for any targeted RSV symptom with baseline score of 1. The time to resolution of targeted RSV symptoms by Day 28 was calculated as the resolution date/time minus the first dose date/time. Targeted RSV symptoms referred to RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).

Time frame:
Up to Day 28
Reported as:
Median · days
Time to Resolution of Targeted RSV Symptoms by Day 28
daysCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Time to Resolution of Targeted RSV Symptoms by Day 283.4 (3.4 to 3.4)NA (NA to NA)—
SecondaryNumber of Participants With Palatability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5

Caregivers were asked to rate how the study drug tasted to their child. A questionnaire was administered to caregivers to assess palatability. Palatability was assessed by caregivers using a questionnaire on Day 1 and Day 5 with response options: Super Good, Good, Maybe Good or Maybe Bad, Bad, or Super Bad.

Time frame:
Days 1 and 5
Reported as:
Count of participants · Participants
Number of Participants With Palatability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5
ParticipantsCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Day 1 - Super Bad—10
Day 1 - Bad—00
Day 1 - Maybe Good or Maybe Bad—00
Day 1 - Good—01
Day 1 - Super Good—00
Day 5 - Super Bad—00
Day 5 - Bad—10
Day 5 - Maybe Good or Maybe Bad—00
Day 5 - Good—01
Day 5 - Super Good—00
SecondaryNumber of Participants With Acceptability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5

Caregivers were asked to evaluate how easy it was for children to take the study drug. A questionnaire was administered to caregivers to assess acceptability. Acceptability was assessed by caregivers using a questionnaire with response options: Super Easy, Easy, Maybe Easy or Maybe Hard, Hard, or Super Hard. The questionnaire evaluated how easy it was for children to take the study drug.

Time frame:
Days 1 and 5
Reported as:
Count of participants · Participants
Number of Participants With Acceptability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5
ParticipantsCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Day 1 - Super Hard000
Day 1 - Hard010
Day 1 - Maybe Easy or Maybe Hard000
Day 1 - Easy001
Day 1 - Super Easy110
Day 5 - Super Hard000
Day 5 - Hard010
Day 5 - Maybe Easy or Maybe Hard001
Day 5 - Easy100
Day 5 - Super Easy000

Adverse events

Collected over All-cause Mortality and Adverse Events: Up to 5 days plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Part A (Group 2) - Obeldesivir (ODV)0/1 (0%)0/1 (0%)0/1 (0%)
Cohort 1: Part A (Group 3) - ODV0/2 (0%)1/2 (50%)2/2 (100%)
Cohort 1: Part A (Group 3) - Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
TachypnoeaRespiratory, thoracic and mediastinal disorders0/11/20/1
Most frequent other events
Most frequent other events
EventCohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - Placebo
Respiratory syncytial virus infectionInfections and infestations0/11/21/1
AsthmaRespiratory, thoracic and mediastinal disorders0/10/21/1
ConstipationGastrointestinal disorders0/11/20/1
BronchiolitisInfections and infestations0/11/20/1
Metapneumovirus infectionInfections and infestations0/11/20/1

Baseline characteristics

The Safety Analysis Set included all study participants who were randomized into the study and had received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(months)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
Mean48 ± NA7 ± 0.76 ± NA17 ± 20.8
Age, Customized
Age, Customized(Participants)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
< 2 years0213
≥ 2 to < 5 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
Female1214
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
Hispanic or Latino1012
Not Hispanic or Latino0202
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White1113
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Part A (Group 2) - Obeldesivir (ODV)Cohort 1: Part A (Group 3) - ODVCohort 1: Part A (Group 3) - PlaceboTotal
United States1214
08

Study locations

56 sites
  • Children's of Alabama
    Birmingham, Alabama 35233, United States
  • Midway Medical Clinic
    Oneonta, Alabama 35121, United States
  • Cohen Children's Medical Center Pharmacy New Pavillion
    Phoenix, Arizona 11040, United States
  • Velocity Clinical Research, Phoenix
    Phoenix, Arizona 85015, United States
  • UCLA (Outpatient Clinic)
    Los Angeles, California 90095, United States
  • Alliance Research Institute
    Lynwood, California 90262, United States
  • Paradigm Clinical Research
    Modesto, California 95355, United States
  • Paradigm Clinical Research Centers, LLC
    San Diego, California 92108, United States
  • FOMAT - Jeffrey Kaplan MD Inc Pediatric Medicine
    Santa Maria, California 93454, United States
  • Velocity Clinical Research, Washington DC
    Washington D.C., District of Columbia 20016, United States
  • Dolphin Medical Research
    Doral, Florida 33172, United States
  • Nona Pediatric Center
    Orlando, Florida 32829, United States
  • PAS Research
    Tampa, Florida 33613, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Velocity Clinical Research, Sioux City
    Sioux City, Iowa 51106, United States
  • Velocity Clinical Research, Lafayette
    Lafayette, Louisiana 70508, United States
  • Boeson Research
    Great Falls, Montana 59405, United States
  • Boeson Research
    Kalispell, Montana 59901, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Velocity Clinical Research - Norfolk
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Child Health Care Associates
    Syracuse, New York 13210, United States
  • Epic Medical Research -Oklahoma
    Chickasha, Oklahoma 73018, United States
  • Tekton Research, LLC
    Yukon, Oklahoma 73099, United States
  • PAS Research
    Pittsburgh, Pennsylvania 15227, United States
  • Helios Clinical Research
    Burleson, Texas 76028, United States
  • Epic Medical Research - DeSoto
    DeSoto, Texas 75115, United States
  • PAS Research
    Edinburg, Texas 78539, United States
  • Helios Clinical Research
    Houston, Texas 77008, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Sunrise Pediatrics
    Houston, Texas 77077, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Pioneer Research Solutions Inc.
    Houston, Texas 77099, United States
  • Radiance Clinical Research
    Lampasas, Texas 76550, United States
  • Pediatric Center
    Richmond, Texas 77469, United States
  • Central Texas Medical Research, LLC
    San Antonio, Texas 78232, United States
  • North Houston Internal Medicine and Pediatric Clinic
    Tomball, Texas 77375, United States
  • Tanner Clinic
    Kaysville, Utah 84037, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Boeson Research PVU
    Provo, Utah 84604, United States
  • Yoshimura Child Clinic
    Akashi, 674-0068, Japan
  • Japan Community Healthcare Organization Kyushu Hospital
    Fkitakyushu, 806-0034, Japan
  • Uchida child clinic
    Fukuoka, 814-0104, Japan
  • Shindo Children's Clinic
    Fukuoka, 814-0121, Japan
  • SEKI Children's CLINIC
    Fukuoka, 814-0123, Japan
  • Ryuseidai Children's Clinic
    Ibaraki, 305-0008, Japan
  • Isesaki Municipal Hospital
    Isesaki, 372-0817, Japan
  • Abe Child Clinic
    Kanagawa, 223-0051, Japan
  • Okada Kodomonomori Clinic
    Kasukabe, 344-0011, Japan
  • Yutaka Children Clinic
    Kobe, 651-2273, Japan
  • Kochi Health Sciences Center
    Kochi, 781-8555, Japan
  • Japan Community Healthcare Organization Chukyo Hospital
    Nagoya, Japan
  • Shimamura Memorial Hospital
    Nerima-ku, 177-0051, Japan
  • Shizuoka Welfare Hospital
    Shizuoka, 420-0005, Japan
  • Shizuoka City Shimizu Hospital
    Shizuoka, 424-8636, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Apr 2025, 1 month.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 20, 2025
StartActual
Mar 5, 2025
Primary completionActual
Apr 16, 2025
CompletionActual
Apr 16, 2025
Results first posted
Jun 8, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06784973
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Mar 5, 2025
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Results posted
Jun 8, 2026
Last update
Jun 8, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeldesivir

Start the discussion